2Sang S, Lambert JD, Yang CS. Bioavailability and stability issues in understanding the cancer preventive effects of tea polyphenols [J]. J Sci Food Agric, 2006, 86(14): 2256-2265.
3Lam WH, Kazi A, Kuhn D J, et al. A potential prodrug fdr a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of ( - )-epigallocatechin gallate [ ( - )-EGCG][ J]. Bioorga & Med Chem, 2004, 12(21): 5587-5593.
5Amidon GL, Lennemis H, Shah VP, et al. A theoretical ba- sis for a biopharmaceutiedrugelassification: the correlation of in vitro drug product dissolution and in vivo bioavailabili- ty[ J. Pharm Res, 1995,12 (3) :413-420.
6Eriksson B, Arfwidsson AC, Frison L, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee re- placement:METHRO I. MElagatran for THRombin inhibi- tion in Orthopaedic surgery[ J]. Thromb Haemost,2002,87 (2) :231-237.
7Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership :provisional BCS. Clas- sification of the world's top oral drugs [ J ]. AAPS J,2009, 11 (4) :740-746.
8Ku Ms, Dulin W. A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept [ J]. Pharma Dev Techno1,2010,17 (3) :258-302.
9Takagi T, Ramachandran C, Amidon GL, et al. A provision- al biopharmaceutical classification of the top 200 oral dru products in the United States, Great Britain, Spain, and Ja- pan [ J ]. Mol Pharm, 2006,3 (6) :631-643.
10Djaldtti R, Inzelberg R, Gilad IN, et al. Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease [J ]. Mov Disord, 2002,17:297-302.
